Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 2, 2010, Pages

  Tran, Lavinia ^a   Kompa, Andrew R ^a,b   Kemp, Will ^c   Phrommintikul, Arintaya ^a,d   Wang, Bing H ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cardiac remodeling; Fibrosis; Rho kinase

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; RHO KINASE; RHO KINASE INHIBITOR; UROTENSIN II;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; GENE; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROCOLLAGEN ALPHA1 GENE; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD PRESSURE; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HEART FAILURE, DIASTOLIC; HEART RATE; INFUSIONS, INTRAVENOUS; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; UROTENSINS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 74949086624     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00942.2009     Document Type: Article

References (29)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Loudenk CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, MartinIJD, Liu IWS, Glover IGI, Wilson S, McNultyIDE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282, 1999.
2. Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol Suppl 45: xi-xii, 1969.
3. Brandenburger Y, Jenkins A, Autelitano DJ, Hannan RD. Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes. FASEB J 15: 2051-2053, 2001.
4. Douglas SA, Tayara L, Ohlstein E, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II (Abstract). Lancet 359: 1990, 2002.
5. Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z, Willette R, N, Ohlstein EH, Giaid A. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81: 125-128, 2003.
6. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
7. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37: 767-772, 2002.
8. Jalil J, Lavandero S, Chiong M, Paz Ocaranza M. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Espan Cardiol 58: 951-961, 2005.
9. Kemp W, Kompa A, Phrommintikul A, Herath CB, Zhiyuan J, Angus P, McLean C, Roberts S, Krum H. Urotensin II modulates hepatic fibrosis and portal haemodynamic alterations in rats. Am J Physiol Gastrointest Liver Physiol 297: G762-G767, 2009.
10. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25: 1783-1788, 2004.
11. Martin J, Denver R, Bailey M, Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32: 697-701, 2005.
12. Nakayama T, Hirose T, Totsune K, Mori N, Maruyama Y, Maejima T, Minagawa K, Morimoto R, Asayama K, Kikuya M, Ohkubo T, Hashimoto J, Kohzuki M, Takahashi K, Imai Y. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides 29: 801-808, 2008.
13. Onan D, Hannan RD, Thomas WG. Urotensin II: the old kid in town. Trends Endocrinol Metabol 15: 175-182, 2004.
14. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294: H1804-H1814, 2008.
15. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438: 159-170, 2002.
16. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35: 59-70, 2003.
17. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88: 1102-1104, 2001.
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367, 1989.
19. Schwarz B, Percy E, Gao XM, Dart AM, Richardt G, Du XJ. Altered calcium transient and development of hypertrophy in β2-adrenoceptor overexpressing mice with and without pressure overload. Eur J Heart Fail 5: 131-136, 2003.
20. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689, 2004.
21. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179: 901-909, 2007.
22. Supino RMTT. Assays. In: Methods in Molecular Biology, edited by O'Hare S and Atterwill CK. Totowa, NJ: Humana, 1995, p. 137-149.
23. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: Involvement of cell adhesion-mediated integrin signaling. Life Sci 72: 1049-1060, 2003.
24. Tolle M, van der Giet M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 29: 743-763, 2008.
25. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104: 1-5, 2003.
26. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. Role of urotensin II in patients on dialysis. Lancet 358: 810-811, 2001.
27. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003.
28. Watson AMD, Lambert GW, Smith KJ, May CN. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertens 42: 373-379, 2003.
29. Zhang YG, Li YG, Liu BG, Wei RH, Wang DM, Tan XR, Bu DF, Pang YZ, Tang CS. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin 28: 36-43, 2007.